SG Americas Securities’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.68M | Buy |
392,835
+286,477
| +269% | +$4.11M | 0.01% | 999 |
|
|
2025
Q4 | $1.51M | Buy |
106,358
+36,938
| +53% | +$363K | ﹤0.01% | 1711 |
|
|
2025
Q3 | $547K | Buy |
69,420
+57,685
| +492% | +$411K | ﹤0.01% | 2037 |
|
|
2025
Q2 | $67K | Sell |
11,735
-89,258
| -88% | -$576K | ﹤0.01% | 2718 |
|
|
2025
Q1 | $824K | Buy |
100,993
+58,496
| +138% | +$541K | ﹤0.01% | 1335 |
|
|
2024
Q4 | $400K | Sell |
42,497
-9,411
| -18% | -$97.8K | ﹤0.01% | 1535 |
|
|
2024
Q3 | $554K | Buy |
+51,908
| New | +$565K | ﹤0.01% | 1595 |
|
|
2024
Q2 | – | Sell |
-24,668
| Closed | -$291K | – | 3004 |
|
|
2024
Q1 | $291K | Buy |
+24,668
| New | +$315K | ﹤0.01% | 1711 |
|
|
2023
Q4 | – | Sell |
-125,014
| Closed | -$1.52M | – | 3217 |
|
|
2023
Q3 | $1.52M | Buy |
+125,014
| New | +$1.61M | 0.02% | 927 |
|
|
2023
Q2 | – | Sell |
-92,256
| Closed | -$1.02M | – | 2583 |
|
|
2023
Q1 | $1.02M | Buy |
92,256
+79,306
| +612% | +$978K | 0.01% | 1123 |
|
|
2022
Q4 | $158K | Sell |
12,950
-47,497
| -79% | -$535K | ﹤0.01% | 2384 |
|
|
2022
Q3 | $631K | Buy |
60,447
+8,229
| +16% | +$91.7K | 0.01% | 1340 |
|
|
2022
Q2 | $561K | Sell |
52,218
-92,568
| -64% | -$762K | 0.01% | 1864 |
|
|
2022
Q1 | $1.37M | Sell |
144,786
-78,601
| -35% | -$737K | 0.01% | 1195 |
|
|
2021
Q4 | $2.58M | Sell |
223,387
-179,419
| -45% | -$2M | 0.01% | 895 |
|
|
2021
Q3 | $3.85M | Buy |
402,806
+355,695
| +755% | +$3.64M | 0.02% | 719 |
|
|
2021
Q2 | $454K | Sell |
47,111
-103,566
| -69% | -$1.01M | ﹤0.01% | 1981 |
|
|
2021
Q1 | $1.49M | Sell |
150,677
-26,672
| -15% | -$413K | 0.01% | 1255 |
|
|
2020
Q4 | $4.09M | Buy |
+177,349
| New | +$3.63M | 0.02% | 610 |
|
|
2020
Q3 | – | Sell |
-382,443
| Closed | -$5.77M | – | 2956 |
|
|
2020
Q2 | $5.77M | Buy |
382,443
+300,040
| +364% | +$3.66M | 0.05% | 305 |
|
|
2020
Q1 | $761K | Buy |
82,403
+68,012
| +473% | +$647K | 0.01% | 1494 |
|
|
2019
Q4 | $140K | Sell |
14,391
-170,038
| -92% | -$1.56M | ﹤0.01% | 2739 |
|
|
2019
Q3 | $1.48M | Buy |
+184,429
| New | +$2M | 0.01% | 1161 |
|
|
2019
Q2 | – | Sell |
-14,845
| Closed | -$202K | – | 3197 |
|
|
2019
Q1 | $202K | Buy |
+14,845
| New | +$181K | ﹤0.01% | 2569 |
|
|
2018
Q3 | – | Sell |
-10,308
| Closed | -$161K | – | 3257 |
|
|
2018
Q2 | $161K | Sell |
10,308
-4,354
| -30% | -$65.8K | ﹤0.01% | 2750 |
|
|
2018
Q1 | $221K | Sell |
14,662
-9,051
| -38% | -$138K | ﹤0.01% | 2368 |
|
|
2017
Q4 | $341K | Buy |
23,713
+12,825
| +118% | +$176K | ﹤0.01% | 2091 |
|
|
2017
Q3 | $164K | Sell |
10,888
-4,229
| -28% | -$55.9K | ﹤0.01% | 2760 |
|
|
2017
Q2 | $152K | Sell |
15,117
-7,281
| -33% | -$58.6K | ﹤0.01% | 2620 |
|
|
2017
Q1 | $160K | Sell |
22,398
-36,035
| -62% | -$228K | ﹤0.01% | 2615 |
|
|
2016
Q4 | $290K | Buy |
58,433
+38,038
| +187% | +$263K | ﹤0.01% | 2060 |
|
|
2016
Q3 | $151K | Buy |
+20,395
| New | +$138K | ﹤0.01% | 2732 |
|
|
2016
Q2 | – | Sell |
-15,519
| Closed | -$131K | – | 2734 |
|
|
2016
Q1 | $131K | Buy |
+15,519
| New | +$110K | ﹤0.01% | 2458 |
|
|
2015
Q4 | – | Sell |
-15,146
| Closed | -$212K | – | 2790 |
|
|
2015
Q3 | $212K | Buy |
+15,146
| New | +$238K | ﹤0.01% | 1424 |
|
|
2015
Q1 | – | Sell |
-12,485
| Closed | -$104K | – | 2709 |
|
|
2014
Q4 | $104K | Buy |
+12,485
| New | +$85.7K | ﹤0.01% | 2893 |
|
|
2013
Q3 | – | Sell |
-10,986
| Closed | -$26K | – | 2976 |
|
|
2013
Q2 | $26K | Buy |
+10,986
| New | +$33.8K | ﹤0.01% | 2223 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
SG Americas Securities's FOLD Position: Q1 2026 in Review
SG Americas Securities increased its Amicus Therapeutics (FOLD) stake by 269% in Q1 2026, buying an estimated $4.11M and bringing the position to 392,835 shares worth $5.68M. The position accounts for 0.01% of the portfolio, ranked #999.
SG Americas Securities first reported a position in FOLD in Q2 2013 and has held it in 36 quarters since. The position peaked at $5.77M in Q2 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- SG Americas Securities held 392,835 shares of Amicus Therapeutics worth $5.68M as of Q1 2026.
- SG Americas Securities bought 286,477 Amicus Therapeutics shares in Q1 2026, an estimated $4.11M.
- Amicus Therapeutics made up 0.01% of SG Americas Securities's portfolio in Q1 2026, its #999 holding.
- SG Americas Securities first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 36 quarters since.
- SG Americas Securities's Amicus Therapeutics position peaked at $5.77M in Q2 2020.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.